BESTforPM || Sitemap <br/><br/>

Home > Sitemap

Saturday 23 October 2021

	Menu

Home

Patient

What is Precision Cancer Medicine?

How does Precision Cancer Medicine work?

Why is Precision Cancer Medicine Important?

Our Solutions

About Us

Latest News

Cancer cells use nerve-cell tricks to spread from one organ to the next
New research suggests that breast and lung tumors metastasize by hijacking a neural signaling pathway, potentially opening the door to better diagnostics and treatments.
Gene that drives ovarian cancer identified
Scientists have pinpointed which specific genes drive - or delay - high-grade serious ovarian carcinoma.
Activating an estrogen receptor can stop pancreatic cancer cells from growing Penn study shows GPER activation in mice can also make tumors more visible to immune system
Activating the G protein-coupled estrogen receptor (GPER) -- a receptor found on the surface of many normal and cancer tissues -- has been shown to stop pancreatic cancer from growing, but may also make tumors more visible to the immune system and thus more susceptible to modern immunotherapy. Researchers observed the effects of GPER activation in human and mouse pancreatic cancer models.
Shining a light on the role of the genome`s dark matter in cancer development Potential role of long non-coding RNAs in pancreatic cancer
Innovative research has shed light on the mysterious role of long non-coding RNAs in the development of pancreatic cancer and suggests potential new targets for precision cancer therapies.
Key driver of the spread of cancer to the brain
Approximately 200,000 cancer patients are diagnosed with brain metastases each year, yet few treatment options exist because the mechanisms that allow cancer to spread to the brain remain unclear. However, a study offers hope for the development of future therapies by showing how a poorly understood gene known as YTHDF3 plays a significant role in the process.
New way to target some rapidly dividing cancer cells, leaving healthy cells unharmed
Johns Hopkins Medicine Scientists say they have found a new way to kill some multiplying human breast cancer cells by selectively attacking the core of their cell division machinery.
Coffee associated with improved survival in metastatic colorectal cancer patients
In a large group of patients with metastatic colorectal cancer, consumption of a few cups of coffee a day was associated with longer survival and a lower risk of the cancer worsening, researchers report in a new study.
Researchers discover the microbiome`s role in attacking cancerous tumors
Researchers have discovered which gut bacteria help our immune system battle cancerous tumors and how they do it. The discovery may provide a new understanding of why immunotherapy, a treatment for cancer that helps amplify immune response, works in some cases, but not others. The findings show combining immunotherapy with specific microbial therapy helps the immune system to recognize and attack cancer cells in three forms of cancer.
Cancer “Liquid Biopsy” Blood Test Gets Expanded FDA Approval
The Food and Drug Administration (FDA) has expanded the approved uses for a blood test, known as a liquid biopsy, that can help doctors pick the best treatments for some people with cancer. The test identifies cancer-related genetic changes in DNA from tumor cells that have been released into the blood.
Nanoparticle Trains Immune Cells to Attack Cancer
Cancer researchers are exploring all kinds of new and creative approaches to immunotherapy, treatments that help the immune system fight cancer. The latest involves nanoparticles that trains immune cells to attack cancer.
Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers
FDA approves encorafenib in combination with cetuximab for metastatic colorectal cancer with a BRAF V600E mutation
Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry trial
FDA grants accelerated approval to pemigatinib for cholangiocarcinoma with an FGFR2 rearrangement or fusion
FGFR2 fusions appear to be much less frequent in tumours arising in the context of chronic liver fluke infection, the most common aetiology in SE Asia.
Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update(2)
Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update
Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers
Larotrectinib for treating advanced solid tumours with TRK fusions [ID1299]
Oncodna logo - wideToggle main menu visibility ENDOMETRIAL CANCER: Data from SGO 2020 indicate survival benefit for the addition of trastuzumab to standard chemo for those with advanced ERBB2-expressing (HER2+) disease (OS 24.4 versus 29.6 months) April 27, 2020 SCIENTIFIC Randomized phase II trial of carboplatin-paclitaxel compared to carboplatin-paclitaxel-trastuzumab in advanced or recurrent uterine serous carcinomas that overexpress Her2/neu (NCT01367002): Updated survival analysis

Sitemap

BESTforPM LINKS

Forms

Biomarker Evaluation & Supervision Team for Personalized Medicine